Elise A. Chong

Dr. Elise A. Chong is an Assistant Professor of Medicine in the Division of Hematology-Oncology at the Perelman School of Medicine, University of Pennsylvania, and a practicing hematologist at the Abramson Cancer Center and Hospital of the University of Pennsylvania. She specializes in lymphoma treatment, with clinical expertise in B-cell and cutaneous T-cell lymphomas, and actively participates in innovative immunotherapy clinical trials for patients aged 18 and older.

Dr. Chong earned her medical degree from the University of Pennsylvania School of Medicine and completed her residency and fellowship training at the Hospital of the University of Pennsylvania, establishing a strong foundation in hematology-oncology.

Her research program centers on advancing lymphoma therapeutics, particularly through CAR-T cell therapy optimization and novel agent development. Key investigations include radiotherapy bridging strategies for CAR-T infusion, genomic profiling of T-cell lymphomas, and checkpoint inhibitor applications in cutaneous T-cell malignancies. This work directly informs her patient-centered clinical approach, translating research insights into improved treatment protocols.

Dr. Chong's 2025 publication record demonstrates exceptional productivity across high-impact journals, with a clear thematic focus on lymphoma treatment innovation. Her work spans clinical trial design, prognostic modeling, neurotoxicity management in cellular therapy, and novel therapeutic combinations, reflecting a commitment to addressing critical challenges in hematologic malignancies.

Operating within the National Cancer Institute-designated Abramson Cancer Center, Dr. Chong contributes to a multidisciplinary team that integrates clinical care, translational research, and patient education. Her collaborative approach extends to numerous institutional and national research initiatives, fostering an environment where clinical observations directly fuel scientific inquiry.